English
Regional settings| Spread | 0.09 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 2.48 |
| Open | 2.5 |
| 1-Year Change | 541.03% |
| Day's Range | 2.38 - 2.52 |
Vivos Therapeutics, Inc. is a medical technology company. The Company is focused on the development and commercialization to dental practices of a patented oral appliance technology and related protocols called the Vivos System. The Company's Vivos System is a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for people with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). The Company’s business model is focused on dentists, and the Company’s program to train dentists and offer them other value-added services in connection with their ordering and use of the Vivos System for patients is called the Vivos Integrated Practice (VIP) program. Its primary product used in the Vivos System is the mRNA appliance, a specifically designed, custom oral appliance that is worn primarily in the evening hours and overnight and is available for adults.
BRIEF: For the nine months ended 30 September 2021, Vivos Therapeutics Inc revenues increased 28% to $12.5M. Net loss increased from $5.8M to $12.9M. Revenues reflect Appliance sales to integrated providers segment increase of 40% to $4.5M, VIP segment increase of 11% to $6.4M. Higher net loss reflects General and administrative increase of 54% to $17.7M (expense), Sales and marketing increase from $1.5M to $4.2M (expense).
